PMID- 27875596
OWN - NLM
STAT- MEDLINE
DCOM- 20170622
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 11
DP  - 2016
TI  - Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 
      2 Diabetes in China.
PG  - e0167190
LID - 10.1371/journal.pone.0167190 [doi]
LID - e0167190
AB  - OBJECTIVE: This study assessed the long-term cost-effectiveness of 
      saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese 
      patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET 
      alone. METHODS: Systematic literature reviews were performed to identify studies 
      directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related 
      events costs which were modified by hospital surveys. A Cardiff Diabetes Model 
      was used to estimate the long-term economic and health treatment consequences in 
      patients with T2DM. Costs (2014 Chinese yuan) were calculated from the payer's 
      perspective and estimated over a patient's lifetime. RESULTS: SAXA+MET predicted 
      lower incidences of most cardiovascular events, hypoglycemia events and fatal 
      events, and decreased total costs compared with ACAR+MET. For an individual 
      patient, the quality-adjusted life-years (QALYs) gained with SAXA+MET was 0.48 
      more than ACAR+MET at a cost saving of  yen18,736, which resulted in a cost saving 
      of  yen38,640 per QALY gained for SAXA+MET versus ACAR+MET. Results were robust 
      across various univariate and probabilistic sensitivity analyses. CONCLUSION: 
      SAXA+MET is a cost-effective treatment alternative compared with ACAR+MET for 
      patients with T2DM in China, with a little QALYs gain and lower costs. SAXA is an 
      effective, well-tolerated drug with a low incidence of adverse events and ease of 
      administration; it is anticipated to be an effective second-line therapy for T2DM 
      treatment.
FAU - Gu, Shuyan
AU  - Gu S
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang Province, China.
FAU - Zeng, Yuhang
AU  - Zeng Y
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang Province, China.
FAU - Yu, Demin
AU  - Yu D
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Metabolic 
      Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin Medical 
      University, Tianjin, China.
FAU - Hu, Xiaoqian
AU  - Hu X
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang Province, China.
FAU - Dong, Hengjin
AU  - Dong H
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161122
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Dipeptides)
RN  - 9100L32L2N (Metformin)
RN  - 9GB927LAJW (saxagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/adverse effects/*analogs & derivatives/economics/therapeutic use
MH  - Asian People
MH  - Cardiovascular Diseases/chemically induced/economics/mortality
MH  - China
MH  - Costs and Cost Analysis
MH  - Diabetes Mellitus, Type 2/drug therapy/*economics/mortality
MH  - Dipeptides/adverse effects/*economics/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypoglycemia/chemically induced/economics/mortality
MH  - Male
MH  - Metformin/adverse effects/*economics/therapeutic use
MH  - *Models, Economic
MH  - *Quality of Life
PMC - PMC5119856
COIS- This study was funded by AstraZeneca. The funders had no role in study design, 
      data collection and analysis, decision to publish, or preparation of the 
      manuscript. This does not alter our adherence to PLOS ONE policies on sharing 
      data and materials.
EDAT- 2016/11/23 06:00
MHDA- 2017/06/24 06:00
PMCR- 2016/11/22
CRDT- 2016/11/23 06:00
PHST- 2016/07/28 00:00 [received]
PHST- 2016/11/09 00:00 [accepted]
PHST- 2016/11/23 06:00 [entrez]
PHST- 2016/11/23 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
PHST- 2016/11/22 00:00 [pmc-release]
AID - PONE-D-16-30005 [pii]
AID - 10.1371/journal.pone.0167190 [doi]
PST - epublish
SO  - PLoS One. 2016 Nov 22;11(11):e0167190. doi: 10.1371/journal.pone.0167190. 
      eCollection 2016.